Albireo Provides First Quarter 2018 Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St bounces as oil cools, inflation risks keeps Fed in focus
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for sharp weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues
May 17, 2018 7:31 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($0.15), versus $1.77 reported last year. Revenue for the quarter came in at $11.2 million versus the consensus estimate of $31.32 million.
The beginning of 2018 has been a landmark period for Albireo, said Ron Cooper, President and Chief Executive... More
